Once-Weekly HIV Tablet Clears Two Phase 3 Tests
Gilead and Merck disclosed detailed Week 48 results from ISLEND-1 and ISLEND-2, supporting islatravir 2 mg plus lenacapavir 300 mg as the first potential complete once-weekly oral HIV regimen. The combination was noninferior to…
